Genome Healthcare Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.12 M
- Company Age 15 Year, 7 Months
- Last Filing with ROC 31 Mar 2021
- Revenue Growth -44.58%
- Profit Growth 294.52%
- Ebitda 678.15%
- Net Worth 4.23%
- Total Assets -49.26%
About Genome Healthcare
Genome Healthcare Private Limited (GHPL) is a Private Limited Indian Non-Government Company incorporated in India on 04 June 2009 and has a history of 15 years and seven months. Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.12 M, as per Ministry of Corporate Affairs (MCA) records.
Kunjan Vora and Khyati Vora serve as directors at the Company.
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U24230GJ2009PTC057151
- Company No.
057151
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Jun 2009
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
What products or services does Genome Healthcare Private Limited offer?
Genome Healthcare Private Limited offers a wide range of products and services, including Antacid Drugs, Rabeprazole Domperidone Capsule, Antihistamines, Levocetirizine Tablet, Antibiotic Tablets & Capsules, Azithromycin Tablets, Pain Relief Drugs & Pharmaceuticals, Antipyretic Medication.
Who are the key members and board of directors at Genome Healthcare?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kunjan Vora  | Director | 28-Mar-2015 | Current |
| Khyati Vora | Director | 28-Mar-2015 | Current |
Financial Performance of Genome Healthcare.
Genome Healthcare Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 44.58% decrease. The company also saw a substantial improvement in profitability, with a 294.52% increase in profit. The company's net worth moved up by a moderate rise of 4.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Genome Healthcare?
In 2019, Genome Healthcare had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Genome Healthcare?
Unlock and access historical data on people associated with Genome Healthcare, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Genome Healthcare, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Genome Healthcare's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
